Loading...
Market
Vertex Pharmaceuticals market share increase in diabetes treatment by end of 2025?
5
Vertex Pharmaceuticals•American Diabetes Association•84th Scientific Sessions•Orlando•Day 90•Katherine Lewin
Resolution / Starting Odds
Increase by less than 5% • 33%
Increase by 5% to 10% • 34%
Increase by more than 10% • 33%
Market analysis reports and financial publications
Story
Vertex Reports Positive Results in Phase 1/2 Study of VX-880 for Type 1 Diabetes at ADA2024 in Orlando
Jun 21, 2024, 08:44 PM
Vertex Pharmaceuticals has announced positive results from its ongoing Phase 1/2 study of VX-880, a stem cell-derived therapy for the treatment of type 1 diabetes. The results, presented at the American Diabetes Association's 84th Scientific Sessions in Orlando, reveal that the therapy can lead to insulin independence and decreased hypoglycemic events. Of the ten patients who completed their 180-day check-in, seven are no longer using insulin. Additionally, all 12 patients who received the full dose of VX-880 demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90, with three achieving insulin independence. Katherine Lewin reported on the findings at ADA2024.
View original story
Similar markets
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Wegovy • 25%
Zepbound • 25%
Ozempic • 25%
Other • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 20% • 33%
20% - 50% • 33%
More than 50% • 34%
0-10% • 25%
11-25% • 25%
26-50% • 25%
More than 50% • 25%
Less than 20% • 33%
20% to 40% • 33%
More than 40% • 34%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Increase by over 5% • 25%
Increase by 1-5% • 25%
No significant change • 25%
Decrease • 25%
Below 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
Above 40% • 25%